Human parvovirus 4 as potential cause of encephalitis in children, India.
(Development and progression)
Benjamin, Laura A.
|Publication:||Name: Emerging Infectious Diseases Publisher: U.S. National Center for Infectious Diseases Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2011 U.S. National Center for Infectious Diseases ISSN: 1080-6040|
|Issue:||Date: August, 2011 Source Volume: 17 Source Issue: 8|
|Product:||Product Code: 2831810 Nucleic Acids NAICS Code: 325414 Biological Product (except Diagnostic) Manufacturing SIC Code: 2833 Medicinals and botanicals|
|Geographic:||Geographic Scope: India Geographic Code: 9INDI India|
Encephalitis is a major cause of death and disability globally. In
Asia, Japanese encephalitis virus is the most commonly recognized cause,
with 30,000-50,000 cases and [approximately equal to] 10,000 deaths
annually (1). However, for most encephalitis cases, the cause is
unknown, even with comprehensive screening for recognized agents (1).
The advent of high-throughput sequencing technologies enabled the direct characterization of microbial nucleic acid from clinical samples and revolutionized the process for identifying potential etiologic agents of disease. A key feature is that the method is unbiased and can detect any nonhost nucleic acid sequences present in a sample. It has the potential to detect expected agents, known but unexpected agents, and novel agents (2).
Human parvovirus 4 (PARV4) is a single-stranded DNA virus first detected in 2005 (3). Infections with PARV4 are accompanied by acute viremia for several weeks (C. Sharp et al., unpub. data), followed by seroconversion for antibody and virus clearance. As observed with another human parvovirus, parvovirus B19, there is long term persistence of viral DNA sequences in several tissues but not the brain (4). We describe 2 children in southern India with suspected encephalitis and high PARV4 levels in their cerebrospinal fluid (CSF).
We obtained CSF from a cohort of children (<16 years of age) hospitalized with a suspected acute central nervous system (CNS) infection at the Vijayanagar Institute of Medical Sciences, Bellary, India, October 2005-October 2007, as previously described (5). Suspected CNS infection was defined as a febrile illness (for <2 weeks) and [greater than or equal to] 1 of the following signs or symptoms: severe headache, altered mental status, seizures, or focal neurologic signs (6).
To investigate whether uncharacterized infectious agents were associated with neurologic disease, we obtained CSF specimens from 12 patients with acute CNS infection (i.e., febrile illness with CSF leukocyte count >5 cells/mm3 or protein >45 mg/dL). These patients had negative diagnostic test results for pathogens known to cause CNS infection in this region of India at the time of investigation (e.g., Japanese encephalitis virus, chikungunya virus, dengue fever virus, and Plasmodium falciparum); in addition, CSF culture was performed and no bacterial organisms were found (5). Total nucleic acid was extracted from whole CSF and randomly amplified as previously described with the modification that 6-nt barcodes were added to the 5' end of the primers used for the amplification (7). The amplified materials were pooled together and processed by using a high-throughput pyrosequencing technique on a GS FLX Titanium Platform (454 Life Sciences/Roche, Branford, CT, USA).
The raw sequence reads were deconvoluted on the basis of the barcode and then processed through a standardized bioinformatic pipeline (2). The sequences of interest were then categorized into taxonomy groups based on the best BLAST (www.ncbi.nlm.nih.gov/BLAST/) hit. For 2 of the 12 patients, patients VES085 and VES065, viral sequences were detected in the CSF.
We identified 17 (92.6%-98.2% sequence identity) distinct sequence reads in the CSF of patient VES085 and 6 (95.6%-98.9% sequence identity) distinct reads from patient VES065 with pairwise identities based on BLASTn alignment of each read to the reference genome (GenBank accession no. EU175855.1). To verify the results, we used PARV4-specific PCR primers to screen all 12 original CSF samples as described (8). Only samples from VES085 and VES065 were positive; all other samples were negative by PCR.
PARV4 viral loads in the 2 CSF samples and the corresponding serum sample from 1 patient collected contemporaneously were semiquantified by limiting dilution PCR by using primers on 5 replicate samples of each dilution. The PCR conditions demonstrated single copy sensitivity (data not shown), and endpoint titers of 50% positivity were calculated by using the ReedMuench formula (8,9). Both the CSF and 1 serum sample demonstrated high endpoint titers, indicating acute infection and substantial virus spread into the CNS of the 2 patients (Table 1).
To genetically characterize PARV4 variants infecting the patients, we generated overlapping sets of amplicons spanning the complete genome of PARV4 from the 3 samples. No variation was seen between the CSF and serum-derived sequences from VES085. The fully assembled coding regions of the variants generated from both patients were compared to previously described PARV4 variants (n = 18 viral proteins 2/1 and n = 19 nonstructural sequences) (Table 2). Phylogenetic analysis demonstrated that both variants belonged to genotype 2 (Figure). All sequences have been submitted to GenBank (accession nos. HQ593530-HQ593532).
Through serologic screening of age-matched controls, we were able to largely rule out the possibility that detection of PARV4 DNA in samples from 2 of the 12 patients was simply incidental to a high background incidence of PARV4 infection in this age group. Although published data on the duration of viremia in patients with acute PARV4 infections has not been directly determined, viral loads as found in the study patients are of relatively short duration in other parvovirus infections (16 days for viral loads >5,000 DNA copies/mL in the case of B19) (11). Furthermore, through testing sequential samples from persons exposed to PARV4, we have found no persons with viremia duration of >6 weeks (C. Sharp et al., unpub. data). Using the 6-week (maximum) estimate and a background incidence of infection of 2.2% per year (based on the detection of 4/41 seropositive children with a mean age of 4.5 years), the likelihood of viremia detection would be at most 0.25%, a figure consistent with the actual measured absence of viremia detection in the control cohort.
PARV4 is a recently identified virus found in human blood and in a variety of tissues but with no known disease association. In this study we detected PARV4 DNA in 2 of 12 CSF samples from patients with suspected encephalitis of unknown cause in southern India. Unfortunately, no samples were available from the wider cohort for further testing. The presence of PARV4 DNA and IgM against PARV4 in acute-phase serum from the 1 child with this sample available further supports the contention that this was an acute infection.
Brain biopsy, the definitive investigation, was not available at the time. More often than not, clinicians have to rely on surrogate markers to diagnose encephalitis (e.g., CSF pleocytosis, febrile illness, and focal neurologic signs in the right clinical context). It is more common to have CSF pleocytosis than not, though of course there are well characterized cases of CNS infection (e.g., dengue) with no pleocytosis (6).
CSF erythrocyte count was not routinely measured in this resource-limited setting. Although it is theoretically possible the parvovirus detected in the CSF could have reflected spillover from a blood-contaminated spinal tap, there was no overt evidence of hemorrhagic CSF. The fact that patient VES085 was febrile with a neurologic syndrome and positive serum IgM, and patient VES065 had similar clinical signs with high PARV4 viral CSF levels suggests that they did indeed have a CNS infection.
PARV4 is primarily found in injection drug users and persons who have received blood products; PARV4 is therefore presumed to be transmitted parenterally. However, the risk for such transmission in the children in our study was low, which supports the possibility of an alternative route of transmission (8,12). HIV testing was not available.
The use of high-throughput sequencing for identifying an unexpected possible cause of CNS infection (PARV4) is cutting edge; this technique's utility also extends to a recent identification of astrovirus in a case of encephalitis (13). With the high seroprevalence of PARV4 infection highlighted in recent reports (5%-37%), there is a clear need to further assess the role of PARV4 in CNS infection across the globe (14,15).
We thank members of the Wang Lab, the Washington University pathogen discovery facility, and Ming-hua Li for their help in performing the experiments; Mike Griffiths for assisting with the expedient transport of sample materials to the United States; Neil Hall for helpful discussions; and Peter Winstanley for initially facilitating this study.
This project was supported in part by Wellcome Trust, Burroughs Wellcome Fund, UK Medical Research Council, and National Institutes of Health grant U54 AI057160 to the Midwest Regional Centre of Excellence for Biodefense and Emerging Infectious Disease Research.
Dr Benjamin is a Wellcome Trust clinical research fellow at the University of Liverpool with an interest in neurology. She is currently pursuing a PhD focusing on the role of infective agents in brain disease.
Author affiliations: University of Liverpool Institute of Infection and Global Health, Liverpool, UK (L.A. Benjamin, P. Lewthwaite, T. Solomon); Walton Centre National Health Service Foundation Trust, Liverpool (L.A. Benjamin, T. Solomon); Vijayanagar Institute of Medical Sciences, Bellary, India (R. Vasanthapuram); Washington University, St. Louis, Missouri, USA (G. Zhao, D. Wang); and University of Edinburgh, Edinburgh, Scotland (C. Sharp, P. Simmonds)
(1.) Solomon T, Thao TT, Lewthwaite P, Ooi MH, Kneen R, Dung NM, et al. A cohort study to assess the new WHO Japanese encephalitis surveillance standards. Bull World Health Organ. 2008;86:178-86. doi:10.2471/BLT.07.043307
(2.) Finkbeiner SR, Li Y, Ruone S, Conrardy C, Gregoricus N, Toney D, et al. Identification of a novel astrovirus (astrovirus VA1) associated with an outbreak of acute gastroenteritis. J Virol. 2009;83:10836-9. doi:10.1128/JVI.00998-09
(3.) Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E. New DNA viruses identified in patients with acute viral infection syndrome. J Virol. 2005;79:8230-6. doi:10.1128/JVI.79.13.8230-8236.2005
(4.) Manning A, Willey SJ, Bell JE, Simmonds P. Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus. J Infect Dis. 2007;195:1345-52. doi:10.1086/513280
(5.) Lewthwaite P, Vasanthapuram R, Osborne JC, Begum A, Plank JL, Shankar MV, et al. Chikungunya virus and central nervous system infections in children, India. Emerg Infect Dis. 2009;15:329-31. doi:10.3201/eid1502.080902
(6.) Solomon T, Dung NM, Vaughn DW, Kneen R, Thao LT, Raeng sakulrach B, et al. Neurological manifestations of dengue infection. Lancet. 2000;355:1053-9. doi:10.1016/S0140-6736(00)02036-5
(7.) Wang D, Urisman A, Liu YT, Springer M, Ksiazek TG, Erdman DD, et al. Viral discovery and sequence recovery using DNA microar rays. PLoS Biol. 2003;1:e2. doi:10.1371/journal.pbio.0000002
(8.) Sharp CP, LeBreton M, Kantola K, Nana A, Diffo Jle D, Djoko CF, et al. Widespread infection with homologues of human parvoviruses B19, PARV4, and human bocavirus of chimpanzees and gorillas in the wild. J Virol. 2010;84:10289-96. doi:10.1128/JVI.01304-10
(9.) Reed LJMH. Simple method of estimating fifty per cent endpoints. Am J Hyg. 1938;27:493-7.
(10.) Sharp CP, Lail A, Donfield S, Simmons R, Leen C, Klenerman P, et al. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis. 2009;200:1119-25. doi:10.1086/605646
(11.) Zaaijer HL, Koppelman MH, Farrington CP. Parvovirus B19 viraemia in Dutch blood donors. Epidemiol Infect. 2004;132:1161-6. doi:10.1017/S0950268804002730
(12.) Panning M, Kobbe R, Vollbach S, Drexler JF, Adjei S, Adjei O, et al. Novel human parvovirus 4 genotype 3 in infants, Ghana. Emerg Infect Dis. 2010;16:1143-6. doi:10.3201/eid1607.100025
(13.) Quan PL, Wagner TA, Briese T, Torgerson TR, Hornig M, Tashmukhamedova A, et al. Astrovirus encephalitis in boy with X-linked agammaglobulinemia. Emerg Infect Dis. 2010;16:918-25.
(14.) Sharp CP, Vermeulen M, Nebie Y, Djoko CF, LeBreton M, Tamoufe U, et al. Changing epidemiology of human parvovirus 4 infection in sub-Saharan Africa. Emerg Infect Dis. 2010;16:1605-7.
(15.) Fryer JF, Kapoor A, Minor PD, Delwart E, Baylis SA. Novel parvovirus and related variant in human plasma. Emerg Infect Dis. 2006;12:151-4.
Address for correspondence: Tom Solomon, Brain Infections Group, Institute of Infection and Globel Health, University of Liverpool, 8th Floor Duncan Bldg, Daulby St, Liverpool L69 3GA, UK; email: tsolomon@ liverpool.ac.uk
Laura A. Benjamin, Penny Lewthwaite, Ravi Vasanthapuram, Guoyan Zhao, Colin Sharp, Peter Simmonds, David Wang, and Tom Solomon
Table 1. Clinical and laboratory characteristics of children with CSF positive for human parvovirus 4, India * ID, date of Age, illness y Clinical course Outcome VES085, 2 Prodomal illness for 12 Discharged 2006 Jan days; febrile with frequent against medical generalized convulsions advice on day during first week of 18 after admission; CSF admission examination on day 12 of illness VES065 3 Prodomal illness for 9 Recovered on 2005 Nov days; febrile, poor day 14 with no appetite, and a residual generalized convulsion on neurologic day 9; CSF examination deficit on day 9 of illness CSF ID, date of WCC Protein, Glucose, illness PCR ([dagger]) mg/dL mg/dL VES085, + 4 59 32 2006 Jan 1.5 x [10.sup.7] copies/mL VES065 + 8 15 60 2005 Nov 3.2 x [10.sup.5] copies/mL Serum ID, date of illness IgM IgG PCR VES085, + + 2006 Jan 5.6 x [10.sup.9] copies/mL VES065 NA NA NA 2005 Nov * CSF, cerebrospinal fluid; ID, patient identification code; WCC, leukocyte count; Ig, immunoglobulin; +, positive; -, negative; NA, not available. ([dagger]) Leukocyte count differential 100% lymphocytes for each patient. Table 2. Percent divergence of the nonstructural coding region of human PARV4-positive encephalitis patients VES065 and VES085, compared with previously described PARV4 variants * Genotype 3, Genotype 2, Patient or genotype aa (nt), n = 1 aa (nt), n = 7 VES065 CSF, n = 1 9.5 (3.5) 3.7 (1.5) VES085 CSF, n = 1 9.4 (3.5) 3.6 (1.5) VES085 serum, n = 1 9.4 (3.5) 3.6 (1.5) Genotype 1, n = 11 8.0 (2.6) 9.3 (2.9) Genotype 2, n = 7 8.6 (2.7) 1.8 (0.7) Genotype 3, n = 1 Genotype 1, VES085 serum, Patient or genotype aa (nt), n = 11 aa (nt), n = 1 VES065 CSF, n = 1 10.3 (3.7) 0.2 (0.0) VES085 CSF, n = 1 10.2 (3.7) 0.0 (0.0) VES085 serum, n = 1 10.2 (3.7) Genotype 1, n = 11 0.9 (0.6) Genotype 2, n = 7 Genotype 3, n = 1 VES085 CSF, VES065 CSF, Patient or genotype aa (nt), n = 1 aa (nt), n = 1 VES065 CSF, n = 1 0.2 (0.0) VES085 CSF, n = 1 VES085 serum, n = 1 Genotype 1, n = 11 Genotype 2, n = 7 Genotype 3, n = 1 * PARV4, human parvovirus 4; CSF, cerebrospinal fluid.
|Gale Copyright:||Copyright 2011 Gale, Cengage Learning. All rights reserved.|